



#### Disclaimer

- This document contains financial information regarding the businesses and assets of Perstorp Holding AB (publ) (the "Company") and its consolidated subsidiaries (the "Group"). Such financial information may not have been audited, reviewed or verified by any independent accounting firm. The inclusion of such financial information in this document or any related presentation should not be regarded as a representation or warranty by the Company, any of its respective affiliates, advisors or representatives or any other person as to the accuracy or completeness of such information's portrayal of the financial condition or results of operations by the Group.
- This document contains information, data and predictions about our markets and our competitive position. While we believe this data to be reliable, it has not been independently verified and, while we are not aware of any material misstatements therein, we make no representation or warranty as to the accuracy or completeness of such information. Additionally, industry publications and such reports generally state that the information contained therein has been obtained from sources believed to be reliable but that the accuracy and completeness of such information is not guaranteed and in some instances state that they do not assume liability for such information. In those cases where third-party data has not proved readily available, we have relied on internal analyses, as well as information obtained from sources such as our customers, suppliers, trade and business organizations connected with the markets in which we operate. We cannot assure you that any assumptions underlying these statements are accurate or correctly reflect the state and development of, or our position in, the industry. While we believe our internal company research is reliable and the market definitions are appropriate, neither such research nor these definitions have been verified by any independent source.
- Certain statements in this document are forward-looking. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance. These factors include, among others: our level of indebtedness and capital structure and the terms of the notes and our other financing arrangements; our strategy, outlook and growth prospects, including our operational and financial targets; the competitive markets faced by both ourselves and our customers; the economic outlook in general and, in particular, economic conditions in the markets of the United States, Europe and Asia, and the expected growth of our markets; our ability to borrow or raise capital; costs and regulations related to contamination or exposure impacts from our operations or products; our expansion plans, including our ongoing geographic expansion and expansion of our production capacity; our ability to develop, market and launch commercially viable products; the cyclical nature of some of the industries in which we operate; our ability to manage and pass on raw material and other input costs; currency fluctuations; loss of key customers or suppliers for certain of our products; changes to or enforcement of governmental and environmental regulations and health and safety requirements across the multiple jurisdictions in which we operate; downtime at our facilities; inability to control our joint ventures or other similar business arrangements; loss of key personnel; ongoing and future tax audits and potential changes in applicable tax regulations; inadequate protection of our intellectual property rights; and expenses and reputational damage resulting from litigation.
- These and other factors could adversely affect the outcome and financial effects of the plans and events described herein. Forward-looking statements contained in this document regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. New risks can emerge from time to time, and it is not possible for us to predict all such risks, nor can we assess the impact of all such risks on our business or the extent to which any risks, or combination of risks and other factors, may cause actual results to differ materially from those contained in any forward-looking statements. The cautionary statements set forth above should be considered in connection with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may issue. Neither the Company nor the Group undertakes any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak only as of the date of this document.

• By attending this presentation, you are agreeing to be bound by the foregoing limitations.

**2** 2 OCTOBER 2018



#### Important notice

- Unless otherwise stated, the financial information presented in this document represents the Group's continuing operations, i.e. excluding:
  - All shares, 100%, in Perstorp Oxo Belgium AB (site Gent), divested in March 2017
  - The stake in Vencorex (the former Coating Additives business unit)



## Agenda

- Business performance
- Financial review
- Summary
- Q&A



## Business performance



Jan Secher
President & CEO



#### Executive summary


- Q3/18 sales amounted to SEK 3,729 m, a 13% increase over last year, resulting from higher selling prices mainly linked to raw material increases together with positive exchange rate impact
- Organic volume based sales growth for the period was -4% vs. Q3/17. Adjusted for the scheduled maintenance shutdown in Stenungsund, the organic volume-based sales growth was about 1%, also affected by some production issues
- EBITDA excluding non-recurring items amounted to SEK 566 m in Q3/18 compared to SEK 575 m in Q3/17. Adjusted for the scheduled maintenance shutdown in Stenungsund, EBITDA excluding non-recurring items amounted to SEK 616 m. Excluding the shutdown effect the third quarter marked a record high LTM EBITDA of SEK 2,331 m
- Q3/18 EBITDA margin amounted to 15,2% (17.5%). Excluding BioProducts, EBITDA margin amounted to 17.1% (20.0%)
- Free cash flow in Q3/18 was SEK 222 m which was SEK 88 m higher than corresponding period last year thanks to lower working capital as well as lower capital expenditure
- Net Debt/LTM EBITDA amounted to 5.7x in Q3/18 versus 5.6x in Q3/17 as net debt continued to be affected by the SEK weakening


S 22 OCTOBER 2018



#### Market overview

- Somewhat softened demand in EMEA and APAC for certain product lines, continued solid demand in Americas
- Higher selling prices in local currencies vs. the same quarter last year linked to higher raw material prices, improved pricing and exchange rate
- Volumes in EMEA were down 6% compared to Q3 last year linked to both the Stenungsund maintenance shutdown and positive impact from competitor outages last year. Sales were 11% higher than Q3 last year
- Volumes in Americas were down 5% compared to Q3 last year mainly driven by Penta, Oxo and Feed & Food product lines linked to Stenungsund shutdown and availability. Sales were 14% above Q3 last year
- Volumes in APAC increased 3% compared to Q3 last year with good growth for the majority of the product lines despite positive impact in last year from competitor outages. Sales were 15% higher than Q3 last year






**7** 22 OCTOBER 2018




## Raw materials and unit margins

- Compared to both Q3/17 and Q2/18 all key raw material prices increased
- Average price for Brent crude oil increased by 45% in Q3/18 vs Q3/17 and was 1% higher than in Q2/18
- Benzene increased 14% in Q3/18 vs. Q3/17 (+5% vs Q2/18)
- Methanol increased 33% in Q3/18 vs. Q3/17 (+10% vs Q2/18)
- Propylene increased 30% in Q3/18 vs. Q3/17 (+7% vs Q2/18)
- Somewhat lower unit margins vs. Q3/17 driven by higher raw material prices
- Unit margins in Specialties & Solutions continued to improve linked to strengthened pricing and positive exchange rate impact
- Advanced Chemicals & Derivatives unit margins were negatively affected by higher raw material prices partly offset by positive exchange rates impact






#### Margins LTM





## Specialities & Solutions

- Strong improvement in unit margins but negative organic volume based growth
  - Organic volume-based sales growth declined by -5% vs. Q3/17 due to lower availability as a result of maintenance shutdowns and low inventories. Market has been tight for most key products which has driven up both sales prices and margins
  - Q3/18 net sales amounted to SEK 876 m, 16% higher than Q3/17 linked both to higher sales prices and positive currency effects
  - EBITDA amounted to SEK 247 m, corresponding to an EBITDA margin of 28% vs. 24% in Q3/17 mainly as a result of improved unit margins and positive currency effects










#### Advanced Chemicals and Derivatives

- Earnings negatively marked by less favorable market situation as well as shutdown effects and some production issues
  - Organic volume-based sales growth declined by -7% vs. Q3/17, due to the scheduled maintenance shut down
    in Stenungsund. Adjusted for the shut down, volumes of most product lines were in line with previous year
  - Q3/18 net sales amounted to SEK 2,356 m, an increase of 13% compared to Q3/17 linked to positive currency rate impact (10% positive impact vs. Q3/17) and higher sales prices (8% positive impact vs. Q3/17) partly offset by lower volumes
  - Q3/18 EBITDA decreased SEK 123 m to SEK 293 from Q3/17, corresponding to an EBITDA margin of 12% (20%) negatively impacted by the scheduled shut down, production disturbances and softer demand for some products lines











#### BioProducts

- Favorable market conditions and volume growth
  - Organic volume-based sales growth was 8% compared to Q3/17
  - Q3/18 net sales amounted to SEK 442 m, an increase of 15% vs. Q3/17. The increase in sales was linked to higher volumes and positive currency rate impact
  - Q3/18 EBITDA amounted to SEK 4 m compared to SEK -5 m in Q3/17, earnings were positively affected by stronger unit margins, improved volumes and positive currency rate impact









#### Financial review



Magnus Heimburg *CFO* 



## Financial highlights Q3 2018

Continuing operations (i.e. excluding Gent)


SEK m	Q3-18	Q3-17	YTD Q3-18	YTD Q3-17	LTM Q3-18	LTM Q3-17	Q2-18
Net Sales	3,729	3,289	11,358	9,990	14,960	13,078	3,949
% growth (y-o-y)	13,4%	18,1%	13,7%	25.1%	14,4%	26.0%	+20.1%
% organic volume based sales growth (y-o-y)	-4,4%	7.2%	0.4%	11.8%	1.8%	14.2%	+5.3%
Marginal Contribution	1,056	1,100	3,313	3,199	4,399	4,128	1,166
% of sales	28.3%	33.4%	29.2%	32.0%	29.4%	31.6%	29.5%
EBITDA, reported	524	571	1,743	1,634	2,205	2.057	615
% of sales	14.1%	17.4%	15.3%	16.4%	14.7%	15.7%	15.6%
EBITDA, excl. non recurring items	566	575	1,796	1,648	2,281	2,109	623
% of sales	15.2%	17.5%	15.8%	16.5%	15.2%	16.1%	15.8%

**13** 22 OCTOBER 2018



## Bridge EBITDA excl. non recurring items


Q3 2018 vs. Q3 2017



- EBITDA decreased by SEK 9 m year-on-year, linked to impact from scheduled maintenance shutdown in Stenungsund and negative impact from higher raw material costs
- Positive exchange rate impact on unit margins



## LTM Development EBITDA<sup>1)</sup>



- Q3/18 EBITDA (SEK 566 m) and LTM EBITDA (SEK 2,281 m) negatively impacted by ca SEK 50 m linked to the scheduled maintenance shutdown in Stenungsund
- Historical EBITDA figures are adjusted for the divestment of Gent operation

15


1) Excluding non-recurring items 22 OCTOBER 2018



#### Free cash flow

- Free cash flow in Q3/18 was SEK 222 m compared to SEK 134 m in Q3/17
- Lower earnings offset by lower capital expenditures and somewhat lower working capital
- Utilization of the trade receivable program amounted to € 115 m (€ 115 m Q3/17) at end of Q3/18
- Free cash flow in Q4/18 expected to be positive

#### Free cash flow SEK m





**6** 22 OCTOBER 2018



## Working capital

- Reported working capital increased by SEK 138 m during Q3/18 vs. Q2/18
- Accounts receivables decreased by SEK 302 m from Q2/18 following lower sales
- Accounts payable decreased by SEK 146 m vs. Q2/18, mainly linked to lower purchases due to the shutdown in Stenungsund
- Inventory value decreased by SEK 17 m vs Q2/18, mainly due to the maintenance shutdown in Stenungsund






17 22 OCTOBER 2018



#### Investments

- Total investments amounted to SEK 167 m in Q3/18 which was SEK 76 m lower than in Q3/17
- Maintenance investments amounted to SEK 134 m in Q3/18 compared to SEK 85 m in Q3/17
- Strategic investments include selective capacity expansions, smaller debottlenecking investments in our key platforms and acquisitions
- Total investment amount for 2018 is estimated to be around SEK 700-750 m






#### Indebtness

#### Current capital structure details

	USD m Equiv.	SEK m <sup>1)</sup>	x EBITDA excl non-rec. <sup>2)</sup>
Cash on balance sheet	-43	-385	
Senior secured notes (€)	556	4,921	
Senior secured notes (\$)	220	1,949	
Net senior secured debt	733	6,485	2,8x
Second lien notes (\$)	420	3,720	
Net second lien debt	1,153	10,205	4,5x
Mezzanine loans (€)	322	2,851	
Other debt	-4	-38	
Net debt, excl. pensions and shareholder loan	1,471	13,018	5,7x

- 1) Fx rates; USD 8.86 and Euro 10.29
- 2) Based on EBITDA excl. non-recurring items of SEK 2,281m
- 3) Including drawn SSRCF

- Net debt, excluding shareholder loan and pension liability decreased by SEK 210 m during Q3/18 mainly related to a stronger SEK primarily against USD and EUR.
- Reported leverage was 5.7x compared to 5.6x at Q3/17
- Available funds per end of Q3/18 amounted to SEK 1,119 m





## Financial performance and leverage





# Summary



Jan Secher
President & CEO

21 22 OCTOBER 2018



### Q3 conclusion and current trading

- Q3/18 sales amounted to SEK 3.729 m, a 13% increase over last year, resulting from higher selling prices mainly linked to raw material increases together with positive exchange rates impact
- Organic volume based sales growth for the period was -4% vs. Q3/17. Adjusted for the scheduled maintenance shutdown in Stenungsund, the organic volume-based sales growth was about 1%, also affected by some production issues
- EBITDA excluding non-recurring items amounted to SEK 566 m in Q3/18 compared to SEK 575 m in Q3/17.
   Adjusted for the scheduled maintenance shutdown in Stenungsund, EBITDA excluding non-recurring items amounted to SEK 616 m. Excluding the shutdown effect the third quarter marked a record high LTM EBITDA of SEK 2,332 m
- Free cash-flow amounted to SEK 222 m (SEK 134 m)
- Net Debt/LTM EBITDA amounted to 5.7x compared to 5.6x during the same period last year but down from 5.8x during Q2/18



# Appendix





#### Free cash flow details

Continuing operations (i.e. excluding Gent)

SEK m	Q3-18	Q3-17	YTD Q3-18	YTD Q3-17	LTM Q3-18	FULL YEAR- 17	Q2-18
EBITDA excl non-rec items	566	575	1,796	1,648	2,281	2,133	623
Change in working capital <sup>1</sup>	-178	-198	-659	-590	-276	-207	-108
Maintenance capex	-134	-85	-303	-220	-389	-306	-94
FCF before strategic capex	254	292	834	838	1616	1,620	422
% of EBITDA excl non-rec.	45	51	46	51	71	76%	68%
Strategic capex	-33	-158	-117	-285	-177	-345	-66
Free cash flow	222	134	717	553	1439	1,275	356
% of EBITDA excl non-rec.	39	23	40	34	63	60%	57%

<sup>1)</sup> excluding exchange rate effects and provisions



## Segment reporting

Continuing operations (i.e. excluding Gent)

SEK m	Q3-18	Q2-18	Q1-18	Q4-17	Q3-17	Q2-17	Q1-17	Q4-16	Q3-16
Net Sales	3,729	3,949	3,680	3,602	3,289	3,288	3,413	3,088	2,784
Specialties & Solutions	876	907	920	868	758	793	785	674	638
Advanced Chemicals & Derivatives	2,356	2,662	2,351	2,244	2,091	2,138	2,129	1,905	1,723
BioProducts	442	329	345	453	386	308	437	464	379
Other/eliminations	69	51	64	37	54	49	62	45	44
EBITDA, reported	524	615	604	462	571	502	561	423	474
Specialties & Solutions	247	256	240	187	179	170	189	117	171
Advanced Chemicals & Derivatives	290	428	394	323	415	369	411	321	302
BioProducts	4	0	-21	14	-5	-26	0	39	12
Other/eliminations	-17	-69	-9	-62	-18	-11	-39	-54	-11
EBITDA excl. non recurring items	566	623	607	485	575	502	571	461	476
Specialties & Solutions	247	257	240	188	179	170	189	122	170
Advanced Chemicals & Derivatives	293	428	396	324	416	369	414	322	302
BioProducts	4	0	-21	14	-5	-26	0	39	12
Other/eliminations	22	-62	-8	-41	-15	-11	-32	-22	-8



### Quarter on quarter development

Continuing operations (i.e. excluding Gent)

SEK m	Q3-18	Q2-18	Q1-18	Q4-17	Q3-17	Q2-17	Q1-17	Q4-16	Q3-16
Net Sales	3,729	3,949	3,680	3,602	3,289	3,288	3,413	3,088	2,784
Marginal Contribution	1,046	1,166	1,101	1,086	1,100	1,038	1,061	929	885
% of sales	28.1%	29.5%	29.9%	30.1%	33.5%	31.6%	31.1%	30.1%	31.8%
EBITDA, reported	524	615	604	462	571	502	561	423	474
% of sales	14.1%	15.6%	16.4%	12.8%	17.4%	15.3%	16.4%	13.7%	17.0%
EBITDA, excl. non- recurring items	566	623	607	485	575	502	571	461	476
% of sales	15.2%	15.8%	16.5%	13.5%	17.5%	15.3%	16.7%	14.9%	17.1%



#### Cash and available funds

SEK m	Q3-18
Unrestricted cash	248
Restricted <sup>1)</sup> and escrowed cash <sup>2)</sup>	137
Cash on Balance Sheet	385

<sup>&</sup>lt;sup>1)</sup> Cash in Perstorp accounts in countries where international movement of funds are restricted <sup>2)</sup> Cash held in escrowed accounts as collateral for different business and financial activities

SEK m	Q3-18
Unrestricted cash	248
Unutilized committed credit facilities	871
Reported Available Funds	1,119



## Currency

#### Period average exchange rates

SEK per LOC	Q3-18	Q3-17	FY-17	LTM Q3-18	LTM Q3-17	Q2-18
USD	8.95	8.14	8.54	8.51	8.72	8.67
Euro	10.41	9.56	9.63	10.12	9.62	10.33
GBP	11.66	10.64	10.99	11.44	11.04	11.79

#### Period end exchange rates

SEK per LOC	Q3-18	Q3-17	Q2-18
USD	8.86	8.11	8.96
Euro	10.29	9.57	10.42
GBP	11.57	10.87	11.75

Source: Swedish Central Bank, Riksbanken